Subtotal $0.00
Retatrutide is an investigational synthetic peptide developed by Eli Lilly. It activates three hormone receptors: GIP, GLP-1 and glucagon. Because of this, it is often described as a triple agonist or “triple G” compound.
GIP and GLP-1 are incretin hormones released by the gut after eating. Glucagon is a pancreatic hormone involved in blood sugar and energy use. Approved drugs such as semaglutide act on GLP-1 alone, and tirzepatide acts on GIP and GLP-1. Retatrutide adds the glucagon receptor.
Retatrutide has been studied in phase 3 clinical trials in adults with obesity or overweight, including people with type 2 diabetes. Trial details are listed on ClinicalTrials.gov, the public U.S. registry of clinical studies.
Current status: Investigational – not FDA-approved.
Investigational means retatrutide has been tested in clinical research but has not been approved by the FDA. It is not available as a prescription medicine in the United States.
Retatrutide is not available by prescription in the United States. Any product sold as retatrutide outside an authorized clinical trial is not an approved medicine, and the FDA has not reviewed its contents, purity or safety.
The FDA has also publicly raised concerns about unapproved GLP-1-type products sold online. Status can change once the FDA completes a review, so the FDA remains the best source for current information.
Peptide Labs does not sell this compound. This page is general information, not medical advice. Our Peptide Guide exists to explain what these compounds are and how they are regulated, not to supply them.
Anyone with questions about retatrutide should speak with a licensed healthcare provider, who can explain the current evidence and the legal status in plain terms.
See the full list of compound profiles in the Peptide Guide. For background on what the label “FDA-approved prescription drug” means, read what "FDA-approved prescription drug" means.
Shop Now
